RESPONSE™
Pharmacogenomic Testing

Pharmacogenomics is the study of how human genetic variation affects an individual’s response to drug therapies. Understanding a patient’s genetic make-up allows a physician to predict how a prescribed drug will relate with that patient, giving the clinician insight into not only clinical efficacy, but also potential undesired drug reactions.

Biologic enzymes found in our liver act upon certain target substrates and then trigger a metabolic chain reaction. Information provided by a pharmacogenomic test can be used to help physicians avoid drugs that would be inefficiently metabolized and guide them towards drugs that use more robust metabolic pathways.

By isolating and examining the regions of a patient’s DNA that code for the enzymes of interest, we can provide the following answers:

How do enzymes interact with their targets and how does the patient's genetic makeup affect these interactions?
How do enzymes interact with their targets and how does the patient's genetic makeup affect these interactions?

Enzymes modify drugs into their active and inactive metabolites. A person’s genetic makeup may seriously affect how well certain enzymes perform.

How well does the patient metabolize drugs and what personal factors are being used to aid in drug selection?
How well does the patient metabolize drugs and what personal factors are being used to aid in drug selection?

RESPONSE™ acts as a lifelong prescribing roadmap, steering the provider towards drugs that are metabolized efficiently and away from those that are not.

Is there a system to identify when a patient is taking a medication that is poorly suited for them?
Is there a system to identify when a patient is taking a medication that is poorly suited for them?

RESPONSE™ acts as a safeguard, protecting both physician and patient from undesirable adverse drug reactions.

How can a physician mitigate drug-drug interactions when a patient is prescribed multiple medications?
How can a physician mitigate drug-drug interactions when a patient is prescribed multiple medications?

RESPONSE™ flags potentially dangerous interactions between drugs and often suggests suitable alternatives.

Why Test?

Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:

More than 85% of the population has detectable variations in their DNA that increase their risk for adverse drug reactions.

Adverse drug reactions are the 4th leading cause of death nationwide with more than 8.6 million cases reported annually.

The FDA highlights pharmacogenomics data for more than 130 prescription medications, indicating their strong support for testing.

Who To Test?

The FDA highlights pharmacogenomics data for more than 130 prescription medications, indicating their strong support for testing.

Patients that experience less than optimal results from prescribed medications.

Patients with a personal or family history of adverse drug reactions in response to certain medications.

Polypharmacy patients; those taking multiple prescription medications for multiple chronic conditions.

View a detailed test menu and more information on RESPONSE™ here:

FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.<br><br>
FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.

There are more than 2,216,000 serious ADRs in hospitalized patients, causing over 106,000 deaths annually.<br><br>
There are more than 2,216,000 serious ADRs in hospitalized patients, causing over 106,000 deaths annually.